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Abstract
Background: Propolis (or bee glue), collected from botanical sources by honey bee, has been used as a popular
natural remedies in folk medicine throughout the world. This study was conducted to assess growth inhibitory
effects of ethanol extracts of propolis (EEPs) from 20 different regions in South Korea on human intestinal bacteria as
well as their human β-amyloid precursor cleavage enzyme (BACE-1), acetylcholinesterase (AChE) inhibitory, antioxidant,
antiproliferative, and anti-human rhinovirus activities.
Methods: The Bonferroni multiple-comparison method was used to test for significant differences in total polyphenol
and flavonoid contents among EEP samples using SAS 9.13 program. Correlation coefficient (r) analysis of the biological
activities of EEP samples was determined using their 50 % inhibition concentration or minimal inhibitory
concentration values and their polyphenol or flavonoid contents in 20 native Korean EEP samples.
Results: The amounts of total polyphenol and flavonoids in the Korean EEP samples ranged from 49 to 239 mg
gallic acid equivalent (GAE)/g EEP (Brazilian, Chinese, and Australian samples, 127–142 mg GAE/g EEP) and from
21 to 50 mg quercetin equivalent (QE)/g EEP (Brazilian, Chinese, and Australian samples, 33–53 mg QE/g EEP),
respectively. Correlation coefficient analysis showed that total polyphenol contents may be negatively correlated with
2,2-diphenyl-1-picrylhydrazyl free radical scavenging activity (r = −0.872) and total flavonoid content has no correlation
with the activity (r = 0.071). No direct correlation between BACE-1 inhibition, AChE inhibition, or antiproliferative
activity and total polyphenol or total flavonoid content in Korean EEP samples was found. Gram-positive and
Gram-negative bacteria were observed to have different degrees of antimicrobial susceptibility to the EEP
samples examined, although ciprofloxacin susceptibility among the bacterial groups did not differ greatly.
Conclusions: Further studies will warrant possible applications of propolis as potential therapeutic BACE-1
blocker, antioxidant, antiproliferative agent, and antimicrobial agent.
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Background
Propolis (or bee glue), a strongly adhesive, resinous nat-
ural substance collected from botanical sources (branches,
flowers, pollen, and buds) by honey bee (Apis mellifera L.)
[1], has been used as a popular natural remedy in folk
medicine throughout the world. Bees use propolis to seal
holes in their honeycombs, smooth out the internal walls,
and protect the entrance toward intruders [2, 3]. Propolis
is generally composed of 50 % resin and balsam, 30 %
wax, 10 % essential and aromatic oils, 5 % pollen, and 5 %
various other substances [3], although the precise com-
position of raw propolis varies with several factors such as
botanical source and geographical zones [1–3].
Propolis has been reported to possess a broad spectrum
of biological activities, such as anticancer, anticomple-
ment, antihypertensive, antihyperalgesic, hepatoprotective,
anti-inflammatory, antioxidant, immunomodulatory, anti-
microbial, and antiparasite properties [1, 3–5]. The chem-
ical variability, aroma, and color (brown, green, red, and
yellow) of propolis significantly depend on its botanical
source, age of the honey preparation, geographical zones,
and collection season [2, 6, 7]. In Brazil, propolis from the
southeast region and Amazon contains chiefly pheny-
lated phenylpropanoids and polyprenylated benzophe-
nones, respectively, whereas geranyl flavonones have
been reported for propolis from the Pacific region, such
as Taiwan and Okinawa [7]. Propolis from eastern
Mediterranean regions, such as Greece, Crete, and
Turkey, may contain predominantly diterpenoids [7].
The variation in the chemical composition of propolis
from different origin also causes the diverse biological
activities [7]. More than 300 constituents, including
aromatic acids and esters, flavonoids (chalcones, flava-
nones, flavones, flavonols, and dihydroflavonols), waxy
acids and terpenoids, were isolated from raw propolis
[1, 2]. In Brazil, 12 distinct groups of propolis have
been classified according to their botanical origin and
biological properties [8]. Very little work exists in rela-
tion to biological properties of native Korean propolis,
although the antioxidant activity of propolis from sev-
eral regions in South Korea have been described by
Ahn et al. [9].
The aim of the current study was to assess total poly-
phenol and flavonoid contents as well as the 2,2-diphe-
nyl-1-picrylhydrazyl (DPPH) free radical scavenging,
antiproliferative, anti-human rhinovirus (HRV), human
β-amyloid precursor cleavage enzyme (BACE-1), and
human acetylcholinesterase (AChE) inhibitory activities
of ethanol extracts of propolis (EEPs) from 20 different
regions in South Korea. In addition, the growth inhibitory
effects of the EEP samples on five harmful intestinal bac-
teria, two nonpathogenic intestinal bacteria, six lactic
acid-producing bacteria, and an acidulating bacterium,
including Gram-positive bacteria and Gram-negative
bacteria, using a microtiter plate-based bioassay and com-
pared with those of ciprofloxacin, a second-generation
fluoroquinolone antibiotic with a broad spectrum [10].
The biological activities of the Korean EEP samples
were compared with those of EEP samples from Brazil
with diverse chemical composition, Australia with vari-
ous biologically active flavonoids, phenylpropanoids,
and stilbenes and prenylated stilbenes, and China with
chemical profiles similar to Korean propolis [11]. A
correlation between total polyphenol or flavonoid con-




nyl tetrazolium bromide) (MTT), DPPH, gallic acid,
quercetin, and sulforhodamine B (SRB) were purchased
from Sigma-Aldrich (St. Louis, MO). 5,5-Dithiobis(2-
nitrobenzoic acid) (DTNB), Folin-Ciocalteu’s phenol
reagent, and acetylthiocholine iodide (ATChI) were
purchased from Sigma-Aldrich. Commercially available
antibiotic ciprofloxacin, anticancer agent cisplatin, and
AChE inhibitors donepezil hydrochloride, huperzine A
and tacrine were supplied by Sigma-Aldrich. Ribavirin
was purchased from Tokyo Chemical Industry (Tokyo,
Japan). Anitbiotic-antimycotic was purchased from
Invitrogen (Grand Island, NY). Recombinant human
BACE-1 and fluorogenic peptide substrate (FPS) Mca-
SEVNLDAEFRK (Dnp) RR-NH2 were purchased from
R&D system (Minneapolis, MN). Brain Heart Infusion
(BHI) broth and Eggerth-Gagnon (EG) agar were pur-
chased from Becton, Dickinson and Company (Sparks,
MD) and Eiken Chemical (Tokyo, Japan), respectively.
Minimum essential medium (MEM), RPMI 1640 medium,
and fetal bovine serum (FBS) were supplied by Life Tech-
nologies (Grand Island, NY). All of the other chemicals
and reagents used in this study were of reagent-grade
quality and available commercially.
Propolis samples and extraction
The 20 native Korean propolis samples (P1–20) used in
this study are listed in Table 1, along with coordinates.
The samples were collected as the crude materials by
beekeepers in various regions of South Korea. Propolis
samples from Australia, Brazil, and China were pur-
chased from Aussia Pharma (Silverwater, Australia),
Uniflora Apicultores Associados (Olimpia, Brazil), and
KangSiNong Biotechnology (Wuhan, China), respect-
ively. Because EEP is one of the richest sources of
phenolic acids and flavonoids [12], these propolis sam-
ples were extracted with ethanol at room temperature
for 1 day, and filtered. The combined filtrated was con-
centrated to dryness by rotary evaporation at 40 °C.
The ethanol extracts were kept at −20 °C until use.
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Determination of total polyphenol and flavonoid contents
Total polyphenol contents in EEP samples were deter-
mined using Folin–Ciocalteu colorimetric method de-
scribed by Zongo et al. [13] with slight modifications. In
brief, 100 μL of 0.2 N Folin–Ciocalteu reagent was
added to 96-well plate (SPL Life Sciences, Pocheon,
Gyeonggi, South Korea) containing 20 μL of each EEP in
80 % ethanol for 5 min at room temperature in darkness.
The 80 μL of sodium carbonate (75 g/L) was added to
each well, and the plate was then incubated for 30 min
at room temperature with slightly shaking in darkness.
The absorbance was determined at 735 nm using a Ver-
saMax microplate reader with SoftMax Pro 5 Software
(serial no. SMP500-18672-LWHU) (Molecular Devices,
Sunnyvale, CA). EEPs were evaluated at the final con-
centration of 100 μg/mL. Gallic acid (0–62.5 μg/mL)
was applied as the standard, and the calibration equation
was Y = 0.0454 X – 0.0056 (R2 = 0.9993), where X is the
gallic acid concentration in μg/mL and Y is the absorb-
ance at 735 nm. Total polyphenol contents were
expressed as mg of gallic acid equivalents (GAE) per g of
EEP samples.
Total flavonoid contents in EEP samples were deter-
mined using AlCl3 colorimetric method [13] adapted to
96-well plate. In brief, 100 μL of 2 % AlCl3 was added to
100 μL of each EEP in 75 % ethanol, and the plate was
then incubated for 15 min at room temperature in dark-
ness. The absorbance was determined at 435 nm using a
microplate reader stated previously. EEPs were evaluated
at the final concentration of 100 μg/mL. Quercetin (0–
50 μg/mL) was used as the standard, and the calibration
equation was Y = 0.0343 X + 0.0177 (R2 = 0.9995), where
X is the quercetin concentration in μg/mL, and Y is the
absorbance measured at 435 nm. Total flavonoid con-
tents were expressed as mg of quercetin equivalents
(QE) per g of EEP samples.
Fluorescence resonance energy transfer enzyme assay
The BACE-1 inhibitory activity of all EEP samples was
evaluated according to the methods of Lv et al. [14] and
Wang et al. [15]. The assay mixtures consisted of 1 μL
of 0.5 μg/μL recombinant human BACE-1, 0.75 μL of
2.5 μg/μL FPS, 47.25 μL of 50 mM sodium acetate
(pH 4.5), and EEP (10–2000 μg/mL) in 2 % dimethyl
sulfoxide (DMSO). They were incubated for 1 h at 25 °C
in darkness, followed by adding 16.6 μL of 2.5 M sodium
acetate to terminate the reaction. The intensity of fluor-
escence was determined using a SpectraMax Gemini XS
plate reader with Softmax Pro PC/MAC Software (serial
no. US 02947) (Molecular Devices, Sunnyvale, CA) at
355 nm excitation and 405 nm emission at room
temperature. The inhibition percentage was calculated ac-
cording to the formula: % inhibition = 100 – [(FS – FS0)/
(FC – FC0)] × 100, where FS and FS0 are the fluorescence
of samples at 60 min and zero time, and FC and FC0 are
the fluorescence of control at 60 min and zero time, re-
spectively [13].
Acetylcholinesterase inhibition assay
The assay procedure was performed using the recombin-
ant human AChE (R&D system, Minneapolis, MN) ac-
cording to the manufacture’s protocol. In brief, the
reaction mixture consisted of 50 μL of AChE (0.044 μg/
mL in 0.1 M sodium phosphate buffer (pH 7.5)) and
EEP (10–2000 μg/mL) in 1 % DMSO. The reaction was
started by adding 50 μL substrate/DNTB mixture
(800 μM ATChI in assay buffer containing 400 μM
DTNB). The reaction mixture was incubated at 37 °C for
1 h. The absorbance was recorded at 410 nm using a
VersaMax microplate reader. The AChE inhibitors done-
pezil hydrochloride, tacrine, and huperzine A [16] served
as positive controls and were likewise formulated.
DPPH radical scavenging assay
DPPH free radical scavenging activity of all EEP sam-
ples was evaluated according to the method described
by Blois [17] with minor modifications. In brief, 100 μL
of 0.4 mM DPPH methanl solution was added to 96-
well plate containing each EEP sample in methanol.
Table 1 Propolis samples supplied by 20 different apiaries in
various geographic regions of South Korea
Sample no. Apiary site (Province) Coordinates
P1 Anseong (Gyeonggi) 37°00'30"N, 127°16'30"E
P2 Icheon (Gyeonggi) 37°15'50"N, 127°29'03"E
P3 Yangpyeong (Gyeonggi) 37°29'32"N, 127°29'16"E
P4 Goyang (Gyeonggi) 37°39'30"N, 126°49'50"E
P5 Wonju (Gangwon) 37°20'15"N, 127°56'47"E
P6 Goesan (Chungbuk) 36°48'45"N, 127°47'20"E
P7 Chungju (Chungbuk) 36°58'12"N, 127°57'09"E
P8 Daejeon 36°22'08"N, 127°22'27"E
P9 Dangjin (Chungnam) 36°53'54"N, 126°37'51"E
P10 Goryeong (Gyeongbuk) 35°43'36"N, 128°15'56"E
P11 Uljin (Gyeongbuk) 36°59'30"N, 129°24'46"E
P12 Jinju (Gyeongnam) 35°09'49"N, 128°02'24"E
P13 Changnyeong (Gyeongnam) 35°32'52"N, 128°29'35"E
P14 Geochang (Gyeongnam) 35°41'19"N, 127°54'44"E
P15 Imsil (Jeonbuk) 35°36'44"N, 127°17'07"E
P16 Buan (Jeonbuk) 35°43'46"N, 126°42'59"E
P17 Jeonju (Jeonbuk) 35°49'17"N, 127°09'17"E
P18 Gunsan (Jeonbuk) 35°58'06"N, 126°44'14"E
P19 Gwangju 35°09'35"N, 126°51'11"E
P20 Jeju (Jeju) 33°14'46"N, 126°33'55"E
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Based on the preliminary test results, the radical scav-
enging activity of each EEP sample was determined
with five to seven concentrations ranging from 5 to
2000 μg/mL. After incubation for 30 min at room
temperature in darkness, the absorbance was measured
at 518 nm by using a VersaMax microplate reader. As-
corbic acid served as a positive control and was likewise
formulated. The radical scavenging ability was calcu-
lated according to the formula: % DPPH free radical
scavenging activity = (1 – As/Ac) × 100, where Ac is the
absorbance of the control (without sample) and As is
the absorbance of the sample.
Cancer cell lines and cell proliferation assay
Three human cancer cell lines used in this study were as
follows: PC-3 (human prostate adenocarcinoma cell line)
and MCF-7 (human breast adenocarcinoma cell line)
purchased from the Korean Cell Line Bank (Seoul, South
Korea); A549 (human lung carcinoma cell line) pur-
chased from the American Type Culture Collection
(ATCC) (Manassas, VA). The PC-3 and MCF-7 cell lines
were cultured with RPMI 1640 containing 10 % FBS and
1 % antibiotic-antimycotic solution under 5 % CO2 and
95 % air at 37 °C, whereas A549 cell line was cultured with
MEM containing 10 % FBS, 1 % antibiotic-antimycotic so-
lution, and 1 % glutamine. Cells were grown in SPL Life
Science cell culture dishes.
The antiproliferative activity of all EEP samples to-
ward the human cancer cell lines examined was evalu-
ated using a MTT assay described by Morgan [18]. In
brief, MTT was dissolved in phosphate-buffered saline
(PBS) (pH 7.4) at 5 mg/mL and sterile-filtered. Cells
were plated at 2 × 104 cells per well in 100 μL of
complete culture medium containing the test EEP sam-
ples (dissolved in DMSO Hybri-Max) in 96-well culture
plates. The final concentration of DMSO Hybri-Max in
all assays was 0.1 % or less. Based on the preliminary
test results, the antiproliferative activity of each EEP
sample was determined with five to six concentrations
ranging from 15 to 1000 μg/mL. The culture plates
were incubated for 2 days in a 37 °C in a humidified at-
mosphere of 5 % CO2. The plates were then washed
with 100 μL PBS. The 100 μL medium containing
0.05 % MTT was added to each well and then incu-
bated for 4 h at the same condition stated previously.
MTT solution was removed and 200 μL DMSO was
added to each well. Finally, the plate was shaken for
10 min to dissolve the purple formazan crystals formed.
Cisplatin served as positive controls and was similarly
formulated. Negative controls only consisted of the
DMSO solution only. The optical density values were
recorded using a VersaMax microplate reader at a
560 nm and a 670 nm reference.
Human rhinovirus serotypes and antiviral assay
A human epithelial adenocarcinoma cervix cell line
HeLa (ATCC CCL-2) was maintained in MEM supple-
mented with 10 % FBS and 0.01 % antibiotic-antimycotic
solution in a humidified incubator (37 °C and 5 % CO2)
[19, 20]. HRV-2 (ATCC VR-1112AS/GP) and HRV-4
(ATCC VR-1114AS/GP) were propagated in HeLa cells
at 37 °C. Virus titers were determined by using cyto-
pathic effects (CPE) in HeLa cells and were expressed as
50 % cell culture infective dose (CCID50) per mL, as de-
scribed previously [19, 20].
The anti-HRV activity of all EEP samples was assessed
by a SRB assay using CPE reduction [19, 20]. In brief,
HeLa cells were seeded onto 96-well culture plates at a
density of 3 × 104 cells per well for 1 day. The culture
medium was then removed and the plates were washed
with PBS. Subsequently, 90 μL of diluted virus suspen-
sion containing CCID50 of the virus stock was put into
the wells, and then 10 μL of MEM supplemented with
30 mM MgCl2 containing four to five concentrations
(0.1–200 μg/mL) of each EEP sample in 0.1 % DMSO
was added to produce an appropriate CPE within 2 days
after infection. After incubation at 37 °C and 5 % CO2
for 2 days, the plates were washed once with 200 μL
PBS. The 100 μL of 0.057 % (w/v) SRB in 1 % acetic acid
solution was added to each well and left at room
temperature for 30 min. The absorbance was recorded
using a VersaMax microplate reader at 562 nm and at
620 nm reference. Ribavirin served as a positive control
and negative controls consisted of the DMSO solution.
Viral inhibition rate (VIR) (%) was calculated according
to the formula [20]: % VIR = (ODtV – ODcV)/(ODcd –
ODcV) × 100, where ODtV is the optical density measured
with a given concentration of the EEP sample in HRV
infected cells; ODcV is the optical density measured for
the control untreated HRV infected cells; ODcd is the
optical density measured for the control untreated HRV
uninfected cells.
Intestinal bacterial strains and growth inhibitory assay
Five harmful bacteria, two nonpathogenic bacteria, six
lactic acid-producing bacteria, and an acidulating bacter-
ium used in this study are listed in Table 2. Stock cul-
tures of the bacterial strains were stored on BHI broth
(pH 7.6) containing 25 % glycerol (v/v) at −70 °C. The
cultures of Escherichia coli ATCC 11775 and Staphylo-
coccus aureus ATCC 12600 were incubated at 37 °C for
1 day under aerobic condition, while the cultures of the
other 12 bacterial strains were incubated at 37 °C for
1 day in an atmosphere of 5 % H2, 15 % CO2, and
80 % N2 in a FA-6 anaerorator (serial no. 98072851)
(Hirayama, Tokyo, Japan) [21]. For bioassay, bacterial
suspensions containing 1 × 105 colony-forming unit
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(CFU)/mL were prepared in EG agar using 24 h subcul-
tures in BHI broth.
A microtiter plate-based bioassay in sterile 96-well
plates was used to determine the minimal inhibitory
concentrations (MICs) of all EEP samples toward the or-
ganisms, as described by Sarker et al. [22]. In brief, ini-
tial EEP samples were prepared in DMSO, and a twofold
dilution series was then formulated in 50 μL BHI broth.
Subsequently, 10 μL bacterial suspension of each strain
was added. Ciprofloxacin served as a positive control
and was similarly formulated. Negative controls con-
sisted of the DMSO solution only. Treated and control
plates were incubated under the same conditions as
those used for bacterial cultures for 24 h. Then, 10 μL of
resazurin solution (270 mg resazurin in 40 mL sterile
distilled water) was added to each well.
Data analysis
MIC (mg/mL) was defined as the lowest concentration
of EEP that visually inhibited bacterial growth using
resazurin indicator. The BACE-1 inhibitory, AChE
inhibitory, and free radical scavenging activity was
expressed as 50 % inhibition concentration (IC50, μg/
mL) of the EEP that is required to cause 50 % BACE-1,
AChE, and DPPH inhibition, respectively. The antipro-
liferative activity was expressed as 50 % inhibition con-
centration (IC50, μg/mL) of the EEP that is required to
reduce the viability of cells to 50 % compared to the
controls. The IC50 values of the EEP samples were cal-
culated using Prism 5 software program (GraphPad
Software, La Jolla, CA). The IC50 values were consid-
ered to be significantly different from one another
when their 95 % confidence limits did not overlap. Re-
sults were expressed as mean ± standard error (SE) of
triplicate samples of three independent experiments.
The Bonferroni multiple-comparison method was used
to test for significant differences in total polyphenol
and flavonoid contents among EEP samples using SAS
9.13 program (SAS Institute, Cary, NC). Correlation co-
efficient (r) analysis of the biological activities of EEP
samples was determined using their IC50 or MIC values
and their polyphenol or flavonoid contents in 20 Ko-
rean EEP samples.
Results
Total polyphenol and flavonoid contents of propolis
samples
The total polyphenol and flavonoid contents in 20
Korean EEP samples were compared with those of
Australian, Brazilian, and Chinese EEP ones (Table 3).
The total polyphenol contents (F = 92.79; df = 22, 46;
P < 0.0001) and flavonoid contents (F = 68.66; df = 22,
46; P < 0.0001) in 23 EEP samples significantly differed.
The total polyphenol contents in 20 Korean EEP sam-
ples ranged from 48.5 to 238.9 mg GAE/g EEP. EEP
samples from P10, P13, P3, and P1 showed higher total
polyphenol contents (238.9–219.5 mg GAE/g EEP)
than those from other regions. The total polyphenol
content of EEP from P20 was the lowest of any of the
propolis examined. The total polyphenol content of
EEP samples from Brazil, China, and Australia was be-
tween 127 and 142 mg GAE/g EEP. The total flavonoid
contents in Korean EEP samples ranged from 20.8 to
49.8 mg QE/g EEP. EEPs from P9, P20, and P2 showed
higher total flavonoid contents (49.8–40.5 mg QE/g
EEP) than those from other regions. The total flavon-
oid content of EEP from P17 was the lowest of any of
the propolis examined. The total flavonoid content of
EEP samples from China, Australia, and Brazil was be-
tween 33 and 53 mg QE/g EEP.
In vitro BACE-1 inhibitory activity
Because BACE-1 is a critical enzyme in the amyloid pre-
cursor protein (APP) amyloidgenic pathway that gener-
ates β-amyloid, the main component of amyloid plaque
in the brain of AD [23], the BACE-1 inhibitory activity
of all EEP samples was elucidated using a fluorescence
resonance energy transfer enzyme assay (Table 4). As
judged by IC50 values, the BACE-1 inhibitory activity of
20 native Korean EEP samples ranged from 25.7 to
291.9 μg/mL. EEP from P7 (IC50, 26 μg/mL) was the
most active propolis, followed by EEP samples from P2,
P5, P1, P6, P10, and P16 (36.3–64.6 μg/mL). IC50 of EEP
samples from China, Australia, and Brazil was between
116.4 and 476.5 μg/mL.





Gram-positive Gram-positive lactic acid-producing
bacteria
Clostridium difficile ATCC 9689 Bifidobacterium bifidum ATCC 29521
Clostridium paraputrificum
ATCC 25780
Bifidobacterium breve ATCC 15700
Clostridium perfringens ATCC
13124
Bifidobacterium infantis ATCC 25962
Staphylococcus aureus ATCC
12600
Bifidobacterium longum ATCC 15707
Lactobacillus acidophilus ATCC 4356
Lactobacillus casei ATCC 393
Gram-negative Gram-positive acidulating bacterium
Bacteroides fragilis ATCC 25285a Clostridium butyricum ATCC 25779
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Human acetylcholinesterase inhibitory activity
Because AChE is one of the major targets of AD [16],
the inhibitory activity of all EEP samples was compared
with that of three anticancer agents (Table 5). As judged
by IC50 values, the anti-AChE activity of 20 native Ko-
rean EEP samples ranged from 15.6 to 327.3 μg/mL. EEP
from P2 (IC50, 15.6 μg/mL) was the most active propolis,
followed by P20 (26.7 μg/mL) and P16 (33.9 μg/mL).
They were significantly less active than either huperzine
A, donepezil hydrochloride, or tacrine (IC50, 0.2–1.2 μg/
mL). IC50 of EEP samples from China, Australia, and
Brazil was between 147.0 and 242.9 μg/mL.
DPPH free radical scavenging activity
The antioxidant activity of all EEP samples was com-
pared with that of an antioxidant agent ascorbic acid
using a DPPH radical scavenging assay (Table 6). Based
on IC50 values, the radical scavenging activity of 20
Korean EEP samples ranged from 43.4 to 269.0 μg/mL.
EEP samples from P1 was the most active propolis,
followed by EEPs from P3, P5, and P10. The inhibitory
activity of the EEP samples was 3.1, 3.8, 4.0, and 4.2
times less active than that of ascorbic acid (IC50, 14 μg/
mL), respectively. IC50 of EEP samples from Australia,
Brazil, and China was between 73.8 and 179.0 μg/mL.
Antiproliferative effect on cancer cell lines
The antiproliferative activity of all EEP samples was
compared with that of a commercial anticancer agent
cisplatin using a MTT assay (Table 7). As judged by IC50
values, the antiproliferative activity of 20 Korean EEP
samples toward PC-3 cell line ranged from 15.9 to
331.6 μg/mL. EEP from P2 was the most active propolis,
followed by EEPs from P7 and P12. The inhibitory activ-
ity of the EEP samples was 3.8, 2.0, and 1.6 times more
active than that of cisplatin (IC50, 61 μg/mL), respect-
ively. IC50 of EEP samples from Australia, Brazil, and
China was between 92.8 and 121.9 μg/mL. Toward
MCF-7 cell line, IC50 of 20 Korean EEP samples was be-
tween 17.7 and 218.2 μg/mL. EEPs from P12 and P20
were the most active propolis and the antiproliferative
Table 3 Total polyphenol and flavonoid contents in 20 Korean,




(mg QE /g EEP)
P1 219.5 ± 5.31a–c 29.7 ± 0.77f–h
P2 148.0 ± 4.32f–i 40.5 ± 0.77b,c
P3 229.0 ± 4.82a,b 23.5 ± 0.15i,j
P4 202.4 ± 4.11b–d 30.4 ± 0.36e–g
P5 196.5 ± 4.28c–e 26.3 ± 0.57g–i
P6 135.9 ± 5.70hi 23.6 ± 0.38i,j
P7 205.6 ± 5.48b–d 35.9 ± 0.57c–e
P8 151.9 ± 5.01f–h 26.5 ± 0.56g–i
P9 205.0 ± 5.98b–d 49.8 ± 0.79a
P10 238.9 ± 4.61a 36.5 ± 0.61b–d
P11 132.3 ± 2.78h,i 25.3 ± 1.27g–j
P12 125.1 ± 5.37i 28.7 ± 0.17f–i
P13 233.5 ± 4.39a,b 28.3 ± 2.13f–i
P14 181.7 ± 4.20d,e 27.6 ± 0.29f–i
P15 183.2 ± 5.75d,e 26.6 ± 0.07g–i
P16 168.7 ± 5.68e–g 37.8 ± 2.02b–d
P17 190.3 ± 5.45c–e 20.8 ± 0.17j
P18 171.6 ± 6.21e,f 26.6 ± 0.20g–i
P19 148.3 ± 5.77f–i 24.4 ± 2.01h–j
P20 48.5 ± 4.08j 42.2 ± 1.75b
Australian 142.4 ± 3.61g–i 38.0 ± 0.90b–d
Brazilian 126.8 ± 4.12h,i 53.0 ± 0.22a
Chinese 132.1 ± 3.28h,i 32.5 ± 0.53d–f
GAE gallic acid equivalent, QE quercetin equivalent, EEP ethanol extract
from propolis
Means followed by the same letter in the column are not significantly different
(P = 0.05, Bonferroni method)
Table 4 BACE-1 inhibitory activity of 20 Korean, Australian,
Brazilian, and Chinese propolis ethanol extracts
Sample IC50, μg/mL (95 % CL) Slope ± SE χ
2a P-value
P1 55.8 (47.7–63.9) 1.8 ± 0.15 2.67 0.996
P2 36.3 (25.2–52.3) 0.9 ± 0.10 7.32 0.961
P3 70.0 (55.9–87.5) 1.1 ± 0.10 5.07 0.983
P4 101.1 (84.7–120.6) 1.6 ± 0.29 5.74 0.981
P5 52.9 (37.3–75.0) 0.9 ± 0.12 8.74 0.931
P6 58.2 (48.8–69.5) 1.5 ± 0.15 3.98 0.991
P7 25.7 (21.8–30.4) 1.2 ± 0.07 3.56 0.989
P8 99.1 (91.4–107.5) 1.6 ± 0.12 2.55 0.997
P9 115.4 (99.7–133.6) 3.4 ± 1.50 2.77 0.997
P10 61.4 (49.1–76.8) 1.4 ± 0.15 6.90 0.974
P11 291.9 (278.0–306.6) 1.3 ± 0.03 1.41 0.999
P12 140.0 (122.0–160.6) 1.2 ± 0.08 3.56 0.992
P13 122.5 (110.9–135.4) 2.5 ± 0.42 3.36 0.995
P14 140.5 (125.5–157.2) 2.2 ± 0.24 3.65 0.994
P15 141.1 (127.8–155.8) 2.0 ± 0.18 3.27 0.995
P16 64.6 (52.1–80.2) 1.7 ± 0.26 4.87 0.987
P17 96.7 (91.4–102.2) 2.3 ± 0.39 2.40 0.997
P18 117.5 (108.7–127.1) 2.0 ± 0.21 2.91 0.996
P19 97.8 (92.3–103.6) 2.3 ± 0.41 2.57 0.997
P20 128.7 (112.6–147.2) 1.3 ± 0.09 3.99 0.997
Australian 127.5 (114.2–142.3) 1.7 ± 0.15 3.60 0.993
Brazilian 476.5 (458.5–495.2) 1.6 ± 0.05 1.30 0.999
Chinese 116.4 (105.4–128.6) 2.7 ± 0.66 3.23 0.995
aPearson’s chi-square goodness-of-fit test
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activity of these samples did not differ significantly from
that of cisplatin. IC50 of EEP samples from Australia,
Brazil, and China was between 61.7 and 144.8 μg/mL.
Toward A549 cell line, IC50 of 20 Korean EEP samples
was between 6.5 and 365.3 μg/mL. EEPs from P1, P7, P8
and P9 (IC50, 6.46–11.0 μg/mL) were the most active
propolis and the antiproliferative activity of these sam-
ples did not differ significantly from that of cisplatin.
IC50 of EEP samples from Australia, Brazil, and China
was between 152.2 and 452.8 μg/mL.
Anti-human rhinovirus activity
The antiviral activity of all EEP samples was compared
with that of the antiviral agent ribavirin using a SRB
assay (Data not shown). EEP sample from Brazil was
5.9 and 5.1 times more toxic toward HRV-2 (IC50, 12.6 μg/
mL) and HRV-4 (15.4 μg/mL) than ribavirin, respectively.
IC50 of the other 22 EEP samples was >100 μg/mL toward
two HRVs.
Growth-inhibiting effect on intestinal bacteria
The growth inhibitory effects of all EEP samples on five
harmful and two nonpathogenic intestinal bacteria as
well as six lactic acid-producing bacteria and an acidu-
lating bacterium examined were compared with those of
the commercial antibiotic ciprofloxacin (Table 8). Re-
sponses varied according to bacterial species and prop-
olis examined. As judged by MIC values, EEP samples
from P6, P9, and P11 showed potent growth inhibitory
activity toward C. difficile ATCC 9689, although the in-
hibitory activity of these compounds was less active than
that of ciprofloxacin. The MIC of EEPs from P12, P9,
and P19 was 1.84, 14.7, and 14.7 mg/mL toward C. para-
putiricum ATCC 25780, C. perfringens ATCC 13124,
and S. enterica serovar Typhimurium ATCC 13311, re-
spectively (ciprofloxacin, 0.062, 0.031, and 0.125 mg/mL).
Toward B. fragilis ATCC 25285, the MIC of EEPs from
Table 5 Human acetycholinesterase inhibitory activity of 20
Korean, Australian, Brazilian, and Chinese propolis ethanol
extracts and three commercial anti-Alzheimer’s disease agents
Sample IC50, μg/mL (95 % CL) Slope ± SE χ
2a P-value
P1 70.0 (56.9–86.1) 1.0 ± 0.12 7.33 0.9113
P2 15.6 (11.2–21.6) 0.6 ± 0.05 3.04 0.9321
P3 55.7 (44.7–69.4) 1.1 ± 0.14 7.71 0.9018
P4 47.9 (39.0–59.0) 1.1 ± 0.14 6.96 0.9128
P5 119.9 (98.2–146.4) 2.4 ± 0.48 12.2 0.9066
P6 89.8 (80.1–100.6) 2.2 ± 0.23 6.75 0.9685
P7 48.0 (40.8–56.55) 1.2 ± 0.12 5.88 0.9406
P8 79.3 (72.6–86.6) 4.8 ± 0.67 6.67 0.9760
P9 103.2 (91.8–116.1) 2.6 ± 0.33 7.56 0.9665
P10 104.2 (89.2–121.7) 2.0 ± 0.26 8.59 0.9459
P11 123.4 (115.1–132.2) 2.6 ± 0.20 4.49 0.9878
P12 61.6 (56.4–67.2) 2.5 ± 0.25 5.57 0.9724
P13 101.6 (84.8–121.7) 2.0 ± 0.32 10.29 0.9242
P14 102.1 (84.8–122.8) 1.8 ± 0.26 9.87 0.9245
P15 104.9 (85.6–128.6) 1.8 ± 0.30 11.04 0.9070
P16 33.9 (26.5–43.2) 1.1 ± 0.13 6.39 0.9012
P17 130.8 (122.5–139.6) 4.1 ± 0.60 5.58 0.9842
P18 124.8 (101.7–153.2) 1.6 ± 0.22 9.94 0.9094
P19 327.3 (297.7–359.7) 2.6 ± 0.26 6.04 0.9785
P20 26.7 (20.7–34.5) 0.9 ± 0.09 4.85 0.9213
Australian 242.9 (231.9–254.5) 3.2 ± 0.22 3.39 0.9940
Brazilian 147.0 (139.4–155.1) 2.9 ± 0.19 3.66 0.9930
Chinese 230.9 (208.7–255.5) 3.6 ± 0.62 7.88 0.9696
Tacrine 1.2 (0.9–1.6) 0.4 ± 0.02 3.87 0.9712
Huperzine A 0.2 (0.1–0.3) 0.4 ± 0.03 5.33 0.9246
DH 0.4 (0.3–0.6) 0.3 ± 0.02 4.78 0.9466
DH donepezil hydrochloride
aPearson’s chi-square goodness-of-fit test
Table 6 DPPH free radical scavenging activity of 20 Korean,
Australian, Brazilian, and Chinese propolis ethanol extracts and a
commercial antioxidant agent ascorbic acid
Sample IC50, μg/mL (95 % CL) Slope ± SE χ
2a P-value
P1 43.4 (36.6–51.4) 1.7 ± 0.16 5.32 0.983
P2 115.3 (100.1–132.9) 1.3 ± 0.11 4.29 0.989
P3 52.7 (44.0–63.3) 1.6 ± 0.17 5.71 0.981
P4 80.2(69.4–92.7) 1.3 ± 0.10 4.28 0.989
P5 56.1 (47.6–66.1) 1.5 ± 0.14 5.10 0.985
P6 97.4 (79.9–118.7) 1.2 ± 0.13 5.76 0.980
P7 73.5 (62.7–86.2) 1.4 ± 0.13 4.87 0.986
P8 159.9 (139.7–183.1) 1.9 ± 0.18 4.44 0.990
P9 81.7 (69.8–95.6) 1.9 ± 0.31 5.76 0.983
P10 58.3 (47.1–72.1) 2.2 ± 0.32 6.73 0.976
P11 161.1 (141.8–183.3) 1.9 ± 0.16 4.20 0.991
P12 235.0 (219.6–251.5) 1.3 ± 0.04 1.96 0.998
P13 67.2 (56.0–80.6) 1.7 ± 0.24 6.03 0.979
P14 135.4 (117.1–156.3) 1.7 ± 0.18 4.80 0.988
P15 98.7 (87.1–111.8) 1.4 ± 0.11 3.89 0.991
P16 81.6 (71.8–92.8) 1.4 ± 0.11 4.00 0.991
P17 74.0 (63.7–86.0) 1.6 ± 0.16 4.89 0.987
P18 96.2 (85.0–109.0) 1.5 ± 0.13 4.05 0.991
P19 202.0 (175.0–233.1) 1.5 ± 0.11 4.39 0.989
P20 269.0 (248.3–291.4) 1.5 ± 0.06 2.44 0.996
Australian 73.8 (49.3–110.5) 0.9 ± 0.12 9.76 0.922
Brazilian 148.1 (121.2–180.9) 1.6 ± 0.22 6.51 0.976
Chinese 179.0 (136.8–234.2) 1.8 ± 0.29 8.59 0.958
Ascorbic acid 14.0 (12.4–15.8) 1.8 ± 0.17 4.45 0.983
aPearson’s chi-square goodness-of-fit test
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P8, P12, and P19 was 3.7, 1.84, and 1.84 mg/mL, respect-
ively (ciprofloxacin, 0.062 mg/mL). The MIC of EEPs from
P9, P12, P14, and P19 was 1.84 mg/mL toward E. coli
ATCC 11775 (ciprofloxacin, 0.062 mg/mL). The MIC of
EEPs from P8 and P19 was 14.7 mg/mL toward B. bifidum
ATCC 29521 and B. longum ATCC 15707 (ciprofloxacin,
0.016 and 0.031 mg/mL). The MIC of EEPs from P12 and
P19 was 14.7 mg/mL toward B. infantis ATCC 25962 and
14.7 and 7.4 mg/mL toward C. butyricum ATCC 25779,
respectively (ciprofloxacin, 0.031 mg/mL). The other EEP
samples were ineffective toward all bacterial strains exam-
ined (MIC, > 30 mg/mL).
Discussion
Propolis contains a wide variety of phenolic com-
pounds, mainly flavonoids, phenolic acids, and their es-
ters [1, 2, 7]. A broad spectrum of biological properties
of propolis [1, 3–5] is related to its phenolic composition
in flavonoids and other phenolic compounds [1, 2, 5]. The
flavonoid content of propolis is attributed to the differ-
ent preferred regional plants collected by honey bees.
Flavonoid chemistry and extensive biological activities,
such as antioxidant, hepatoprotective, antimicrobial,
anti-inflammatory and anticancer, have been well docu-
mented by Nijveldt et al. [24] and Kumar and Pandey [25].
The total polyphenol (TP) and flavonoid (TF) contents
were reported in propolis from Algeria (TP, 55–279 mg/g,
TF, 10–69 mg/g) [26], Argentina (TP, 257–393 mg/g, TF,
66–133 mg/g) [27], Brazil (TP, 94–149 mg/g, TF, 6–21 mg/g)
[28], China (TP, 43–302 mg/g, TF, 8–162 mg/g) [6],
Greece and Cyprus (TP, 80–338 mg/g; TF, 9–183 mg/g)
[29], India (TP, 159.10 mg/g; TF, 57.25 mg/g) [30], Japan
(TP, 53–431 mg/g; TF, 18–113 mg/g) [31], Morocco (TP,
0.74–91.22 mg/g; TF, 0.20–34.27 mg/g) [32], Poland
(TP, 150–197 mg/g; TF, 36–62 mg/g) [33], Portugal (TP,
151–329 mg/g) [34], South Korea (TP, 85–283 mg/g; TF,
16–135 mg/g) [9], and Turkey (TP, 115–210 mg/g) [35].
In the current study, the total polyphenol and flavonoid
Table 7 Antiproliferative activity of 20 Korean, Australian, Brazilian, and Chinese propolis ethanol extracts and a commercial
anticancer agent cisplatin toward three cancer cell lines
Sample
PC-3 cell MCF-7 cell A549 cell
IC50, μg/mL (95 % CL) Slope ± SE IC50, μg/mL (95 % CL) Slope ± SE IC50, μg/mL (95 % CL) Slope ± SE
P1 54.0 (44.6–65.4) 0.7 ± 0.07 58.0 (50.6–66.4) 1.5 ± 0.14 6.5 (4.4–9.5) 0.8 ± 0.10
P2 15.9 (13.7–18.4) 1.2 ± 0.10 38.6 (33.6–44.3) 2.5 ± 0.35 20.2 (17.1–23.8) 0.7 ± 0.05
P3 49.8 (42.1–59.0) 0.9 ± 0.08 87.9 (71.0–108.8) 1.0 ± 0.13 164.5 (141.6–191.2) 0.7 ± 0.05
P4 69.7 (62.8–77.3) 0.9 ± 0.05 218.2 (184.9–257.4) 1.4 ± 0.14 61.1 (49.1–76.1) 0.9 ± 0.09
P5 44.2 (37.0–53.0) 1.1 ± 0.11 134.2 (106.1–169..6) 1.1 ± 0.14 40.9 (33.6–49.8) 0.9 ± 0.08
P6 58.2 (49.5–68.5) 1.1 ± 0.10 56.4 (49.7–64.0) 2.0 ± 0.22 16.3 (12.5-21.2) 0.9 ± 0.11
P7 29.9 (24.3–36.8) 1.2 ± 0.13 31.1 (28.2–34.4) 1.5 ± 0.09 9.8 (7.4–13.1) 0.7 ± 0.07
P8 59.6 (47.3–75.0) 1.1 ± 0.14 78.8 (73.6–84.4) 4.4 ± 0.42 11.0 (8.5–14.2) 0.7 ± 0.08
P9 77.9 (68.3–88.8) 0.9 ± 0.07 47.7 (41.8–54.4) 1.8 ± 0.19 9.9 (8.0–12.2) 1.0 ± 0.12
P10 228.8 (189.5–276.3) 0.7 ± 0.06 109.5 (90.2–132.9) 1.2 ± 0.15 365.3 (298.5–447.1) 1.2 ± 0.15
P11 44.0 (35.1–55.1) 1.4 ± 0.19 98.3 (82.6–116.9) 1.3 ± 0.15 65.3 (61.1-69.8) 4.6 ± 0.91
P12 36.7 (29.5–45.6) 1.1 ± 0.14 17.7 (15.5–20.2) 2.0 ± 0.23 70.7 (57.9–86.3) 0.5 ± 0.05
P13 106.6 (90.9–125.0) 0.7 ± 0.05 75.9 (68.3–84.5) 1.2 ± 0.08 262.1 (225.9–304.2) 1.2 ± 0.11
P14 75.3 (68.9–82.3) 1.4 ± 0.21 26.0 (22.8–29.6) 4.5 ± 1.17 176.1 (143.5–215.9) 1.2 ± 0.14
P15 70.2 (56.8–86.9) 0.7 ± 0.06 104.1 (91.3–118.7) 0.8 ± 0.05 73.5 (60.6-89.1) 5.9 ± 2.76
P16 331.5 (266.7–412.2) 0.6 ± 0.05 79.2 (70.8–88.6) 1.9 ± 0.017 127.1 (103.4–156.3) 1.0 ± 0.12
P17 331.6 (279.8–392.9) 0.8 ± 0.06 98.1 (81.3–118.3) 1.3 ± 0.015 86.7 (73.4–102.4) 2.2 ± 0.35
P18 76.4 (66.3–88.0) 1.0 ± 0.07 145.1(122.6–171.8) 1.2 ± 0.013 115.0 (97.6–135.6) 2.3 ± 0.37
P19 161.0 (131.4–197.1) 0.5 ± 0.03 49.8 (48.0–51.8) 3.9 ± 0.23 64.9 (54.1–78.0) 0.7 ± 0.07
P20 17.1 (13.9–21.1) 1.0 ± 0.11 19.8 (17.6–22.3) 2.2 ± 0.28 43.8 (38.8–49.3) 2.7 ± 0.39
AU 92.8 (78.5–109.7) 2.0 ± 0.29 144.8 (134.3–156.1) 3.2 ± 0.32 152.2 (126.3–183.3) 1.9 ± 0.30
BA 105.2 (96.8–114.3) 2.1 ± 0.16 61.7 (54.7–69.7) 1.8 ± 0.16 330.2 (287.7–379.1) 4.9 ± 0.89
CN 121.9 (115.1–129.1) 1.5 ± 0.06 122.5 (108.1–138.7) 1.7 ± 0.15 452.8 (361.8–566.5) 1.1 ± 0.13
CPN 61.5 (50.9–74.4) 1.1 ± 0.11 17.6 (15.3–20.3) 1.5 ± 0.15 6.2 (4.6–8.5) 1.0 ± 0.14
AU Australian; BA Brazilian, CN Chinese, CPN cisplatin
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contents of 20 native Korean EEP samples were between
49 and 232 mg/g and between 21 and 50 mg/g,
respectively, although the polyphenol and flavonoid
contents of propolis stated previously were 31 and
431 mg/g and between 3 and 183 mg/g, respectively.
Certain Korean propolis samples examined possessed
considerable total polyphenol and flavonoid contents,
as compared with either Australian, Brazilian, or Chin-
ese propolis samples examined. This finding indicates
that propolis with high polyphenol and flavonoid con-
tents have to be selected for commercial propolis
products because of the biological significance of the
polyphenols and flavonoids [1, 2, 5].
BACE-1 [36] and AChE [16] are two of the major tar-
gets of AD. There are two major neuropathological
hallmarks of AD including neurofibrillary tangles con-
sisting of hyperphosphorylated tau protein and extra-
cellular amyloid plaques accumulation of β-amyloid
peptides. β-Amyloid was generated via sequential pro-
teolytic processing of APP by BACE-1 and γ-secretase
in APP amyloidogenic processing pathway [37, 38].
BACE-1 is a prime drug target for inhibiting β-amyloid
generation because it is responsible for initiating β-
amyloid production [39]. No information, however, is
available concerning the BACE-1 inhibitory activity of
propolis and its constituents. Brazilian propolis im-
proved cognitive function in the patients with mild cog-
nitive impairment that was deemed as a prodromal
stage of AD [40]. In addition, inhibition of AChE, re-
sponsible for the breakdown of acetylcholine in the
neural synapse, is a possible strategy for treatment of
AD, which is characterized by a decline in cognitive
function and mental atrophy. Propolis with a high phe-
nol content may be an alternative for prevention and/or
retardation of AD symptoms because phenols and fla-
vonoids inhibit AChE activity [41]. The anti-AChE ac-
tivity was reported in propolis from India (IC50,
43.46 μg/mL) [42] and Morocco (43–743 μg/mL) [32].
In the current study, IC50 of 20 native Korean EEP
samples was between 15.6–327.3 μg/mL and the anti-
AChE activity of the EEPs was lower than that of
either donepezil hydrochloride, tacrine, or huperzine
A. Certain Korean propolis samples exhibited good
BACE-1 inhibitory activity (IC50, < 100 μg/mL) and
were more pronounced in the inhibitory activity than
either Australian, Brazilian, or Chinese propolis
examined. Many peptidomimetics and heterocyclic
compounds have been evaluated as BACE-1 inhibitors
[43, 44]. However, none of these have been success-
fully developed as anti-AD drugs. These results verify
that the Korean propolis merit further study as a
potential anti-AD agents.
Antioxidants, which scavenge free radicals such as
superoxide (O2), hydroxyl (OH), and peroxyl (OOH,
ROO) radicals, are known to possess an important role
in preventing these free radical-induced diseases, such as
aging, cardiovascular disease, rheumatoid arthritis,
cancer, diabetes, and neurological disorders (AD and
Parkinson’s disease) and inflammation [45]. The flavo-
noids are powerful antioxidants, capable of scavenging
free radicals [24, 25]. The DPPH free radical scaven-
ging activity was reported in propolis from Algeria
(IC50, 19.4– > 50 μg/mL) [26], Argentina (25–37.5 μg/
mL) [46], Brazil (17.13–83.60 μg/mL) [28], China
(32 μg/mL) [47], Greece (138–1557 μg/mL) [48], India
(70 μg/mL) [30], Morocco (8–1813 μg/mL) [32], and
Portugal (6.22–52 μg/mL) [34]. In the current study, IC50
of 20 native Korean EEP samples were between 43 and
269 μg/mL, although IC50 of propolis stated previously
was 6 and 1813 μg/mL. Certain Korean propolis samples
exhibited good antioxidant activity (IC50, < 100 μg/mL)
and the activity of these samples and Australian propolis
sample did not differ significantly from each other. Our
current finding indicates that the Korean propolis merit
further study as a potential antioxidant, although the
Table 8 Minimal inhibitory concentrations (MICs) of Korean
propolis ethanol extracts and a commercial antibiotic
ciprofloxacin toward four harmful and two nonpathogenic
intestinal bacteria




C. difficile ATCC 9689b 3 P6 (1.84), P9 (1.84),
P11 (1.84), CFd (0.031)
C. paraputrificum ATCC 25780b 1 P12 (1.84), CFd (0.062)
C. perfringens ATCC 13124b 1 P9 (14.7), CFd (0.031)
S. aureus ATCC 12600b 0 CFd (0.031)
B. fragilis ATCC 25285c 3 P8 (3.7), P12 (1.84),
P19 (1.84), CFd (0.062)
E. coli ATCC 11775c 4 P9 (1.84), P12 (1.84),
P14 (1.84), P19 (1.84),
CFd (0.062)
S. enterica Typhimurium ATCC
13311c
1 P19 (14.7), CFd (0.125)
B. bifidum ATCC 29521b 1 P8 (14.7), CFd (0.016)
B. infantis ATCC 25962b 2 P12 (14.7), P19 (14.7),
CFd (0.031)
B. breve ATCC 15700b 0 CFd (0.031)
B. longum ATCC 15707b 1 P19 (14.7), CFd (0.031)
L. acidophilus ATCC 4356b 0 CFd (0.062)
L. casei ATCC 393b 0 CFd (0.031)
C. butyricum ATCC 25779b 2 P12 (14.7), P19 (7.4),
CFd (0.031)
aThe other Korean propolis samples and three foreign (Austrailian, Brazilian,
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activity of these propolis samples was lower than that of
ascorbic acid.
The antiproliferative activity of propolis and its con-
stituents toward various cancer cell lines have been well
documented by Watanabe et al. [12] and Chan et al.
[49]. The antiproliferative activity toward PC-3 cell line
was reported in propolis from Brazil (optimal dose,
40 μg/mL) [50] and India (IC50, 41.8–134.5 μg/mL) [51].
The antiproliferative activity toward MCF-7 cell line was
reported in propolis from Cuba (1–25 μg/mL) [52], India
(13 μg/mL) [42] and (26.88–104 μg/mL) [51], Indonesia
(47.45 μg/mL) [53], Java (37.8–276.45 μg/mL) [54],
Malta (67 μg/mL) [55], Portugal (36–182 μg/mL) [56],
and Turkey (125 μg/mL) [57]. The antiproliferative ac-
tivity toward A549 cell line was reported in propolis
from Cuba (IC50, 35.48–99.5 μg/mL) [58], India (10 μg/
mL) [42], and Tunisia (200 μg/mL) [59]. In the current
study, IC50 of 20 native Korean EEP samples toward
PC-3, MCF-7, and A549 cell lines were between 15.9
and 331.6 μg/mL, between 17.7 and 218.2 μg/mL, and
between 6.5 and 365.3 μg/mL, respectively, although
IC50 of propolis stated previously was between 41.8–
134.5 μg/mL, between 1 and 276.45 μg/mL, and be-
tween 10 and 200 μg/mL. Certain Korean propolis sam-
ples exhibited good antiproliferative activity and were
more pronounced in the activity than either Australian,
Brazilian, or Chinese propolis samples. Of them, the ac-
tivity of some propolis samples toward PC-3, MCF-7,
and A549 cells was comparable to that of the antican-
cer agent cisplatin. Our current finding indicates that
the Korean propolis merit further study as a potential
anticancer agent.
The antimicrobial activity of propolis toward various
pathogens have been well noted [3–5]. In humans, many
species of bacteria (~500–1000 species) reside in the in-
testinal tract as a complex and dynamic ecosystem [60].
Major functions of the microbiota include metabolic ac-
tivities that result in salvage of energy and absorbable
nutrients, trophic effects on intestinal epithelia (cell pro-
liferation and differentiation) and on immune structure
and function, and protection of the colonized host
against invasion by alien microbes (barrier effect) [61].
The microbiota might also be an essential factor in cer-
tain pathological disorders, including multisystem
organ failure, colon cancer, and inflammatory bowel
diseases [61]. In addition, prolonged treatment with an-
tibiotics has often produced resistance to the drugs by
pathogenic microorganisms [62], which is a major glo-
bal public health problem in both developed and devel-
oping countries. Sometimes, serious side effects of
antibiotics occur, such as taste disturbances, nausea,
diarrhea, dyspepsia, headache, and angioedema, as well
as disturbance of human gastrointestinal microflora
[62, 63]. Alternative antibacterial agents with novel
modes of action and low toxicity are urgently needed. It
has been reported that propolis samples from Argentina
[64], France [65], and Greece and Cyprus [29] is effective
toward Gram-positive bacteria, exerting a limited activity
toward Gram-negative bacteria. Boyanova et al. [66] re-
ported that Bulgarian EEP inhibited 97 % (29 of 30 strains)
of the nonspore-forming Gram-positive bacteria and 91 %
(40 of 44 strains) of the Gram-negative bacteria.
In the current study, the Gram-positive and Gram-
negative bacteria were observed to have different de-
grees of antimicrobial susceptibility to the EEP samples
examined, although ciprofloxacin susceptibility among
the bacterial groups did not differ greatly. EEP samples
from P6, P9 and P11 and P12 exhibited pronounced
growth inhibitory activity toward pathogenic Gram-
positive bacteria C. difficile ATCC 9689 and C. parapu-
tiricum ATCC 25780, respectively. EEP samples from
P8 and P9 and P14 were active toward nonpathogenic
Gram-negative bacteria B. fragilis ATCC 25285 and E. coli
ATCC 11775, respectively, whereas EEP samples from P12
and P19 were active toward both Gram-negative bacteria.
However, the propolis samples from Austrailia, Brazil,
and China were ineffective toward five harmful bacteria
and two nonpathogenic bacteria. Boyanova et al. [66]
reported that Bulgarian EEP inhibited 35 % (7 of 20
strains) of Clostridium strains, including C. difficile (13
strains) and C. perfringens (2 strains), and 82 % (9 of 11
strains) of B. fragilis group strains. Ugur et al. [67]
found growth inhibitory activity of EEP samples from
Brazil and Bulgaria toward E. coli MU 8, MU 11, and
MU 23, whereas no inhibitory activity of EEP samples
from Argentina toward E. coli ATCC 25922 [64]. Inter-
estingly, six lactic acid-producing bacteria were less
susceptible than either harmful or nonpathogenic bac-
teria to Korean EEP samples. Detailed tests are needed
to fully understand the different susceptibility of the
EEPs to bacteria. This finding indicates that low con-
centrations of active Korean propolis extracts could be
used in fermented or nonfermented products and drink
products, aiming to selectively inhibit the growth of
pathogenic bacteria.
Correlation between biological activity and phenolic
compound contents has been well studied. High correl-
ation between the total phenolic and flavonoids content
and the free radical scavenging activity was reported in
propolis samples from Argentina [46], Greece and
Cyprus [29], Japan [31], and Poland [33]. Negative or no
direct correlation between them was reported in prop-
olis from Morocco [32] and in propolis from Brazil [68]
and Greece [48], respectively. For the AChE inhibition,
negative correlation between the total phenolic and fla-
vonoids content and IC50 was reported in propolis sam-
ples from Morocco [32]. For the antiproliferative activity
toward MCF-7 cell line, negative correlation between
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the total polyphenol content and IC50 was reported,
whereas positive correlation between the total flavonoid
content and IC50 was reported [56]. For the antimicro-
bial activity, strong correlation between the total phen-
olic and flavonoids content and MIC was reported in
propolis from Spain [69], whereas no direct correlation
between them was also reported in propolis from Brazil
[68] and Greece and Cyprus [29]. In the current study,
correlation coefficient (r) analysis showed that total poly-
phenol contents may be negatively correlated with
DPPH free radical scavenging activity (r = −0.872) and
total flavonoid content has no correlation with the activ-
ity (r = 0.071) (Table 9). No direct correlation between
BACE-1 inhibition, AChE inhibition, or antiproliferative
activity and total polyphenol or total flavonoid content
in Korean EEP samples was found.
Conclusions
Korean propolis-derived preparations could be useful in
food and beverages to prevent various diseases in which
free radicals, neurodegenerative causes, or pathogenic
bacteria are implicated as propolis administration to
humans does not lead to side effects [12]. For the prac-
tical use of the preparations as novel propolis-derived
products to proceed, further research is needed to es-
tablish safety to humans and whether the biological ac-
tivities are exerted in vivo after consumption of the
products by humans. Propolis, administered orally to
mice at levels up to 4000 mg/kg/day for 2 weeks, had
no effect, although it has been identified clinically as an
allergen [3]. Lastly, detailed tests are needed to under-
stand how to improve biological potency and stability
for eventual commercial development.
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